



## Solenio Therapeutics to Participate in Piper Sandler 36th Annual Healthcare Conference

November 27, 2024 1:00 PM EST

REDWOOD CITY, Calif., Nov. 27, 2024 (GLOBE NEWSWIRE) -- Solenio Therapeutics, Inc. ("Solenio") (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced that management will participate in a fireside chat at the Piper Sandler 36<sup>th</sup> Annual Healthcare Conference on Thursday, December 5, 2024, at 9:00 AM Eastern Time.

A live audio webcast and replay of the fireside chat will be available in the Investors section on the Company's website at [www.solenio.life](http://www.solenio.life).

### **About Solenio Therapeutics, Inc.**

Solenio is focused on the development and commercialization of novel therapeutics for the treatment of rare diseases. An NDA for its lead candidate, DCCR (diazoxide choline) extended-release tablets, a once-daily oral tablet for the treatment of Prader-Willi syndrome (PWS) is currently under review by the FDA and was granted Priority Review. For more information, please visit [www.solenio.life](http://www.solenio.life).

### **Corporate Contact:**

Brian Ritchie  
LifeSci Advisors, LLC  
212-915-2578



Source: Solenio Therapeutics